Optimum anthracycline-based chemotherapy for early breast cancer

The Lancet Oncology
J W Adlard, D J Dodwell

Abstract

Adjuvant chemotherapy improves the overall survival of women treated after surgery for early breast cancer. Several trials have suggested that anthracycline-containing regimens are more effective than those that do not contain anthracyclines. A modest overall benefit has also been confirmed by the Early Breast Cancer Trialists' Collaborative Group overview. Newer agents, such as the taxanes, are now being tested in the adjuvant setting in randomised trials. The control group of such studies should receive the optimum standard treatment. There are several anthracycline-based regimens in common use, varying in terms of the type of anthracycline used, the dose, and drug scheduling. We review the available evidence and consider whether the optimum anthracycline-containing chemotherapy schedule has now been identified.

References

Jul 5, 1992·The New England Journal of Medicine·R E CurtisR N Hoover
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E EngelsmanR Sylvester
Aug 1, 1989·International Journal of Radiation Oncology, Biology, Physics·D P DermanW R Bezwoda
Jan 1, 1987·Acta Oncologica·J HrafnkelssonM Söderberg
Feb 15, 1995·JAMA : the Journal of the American Medical Association·G BonadonnaP Valagussa
Sep 25, 1998·Journal of the National Cancer Institute·A D ThorE T Liu

❮ Previous
Next ❯

Citations

Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·H-J SennA S Coates
Jun 29, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·E TsiambasA Karameris
Apr 24, 2007·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Evangelos TsiambasPetros Karakitsos
Jul 9, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aron GoldhirschHans-Jörg Senn
May 12, 2016·Scientific Reports·Jose Felix Moruno ManchonAndrey S Tsvetkov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.